Akorn, Inc. (NASDAQ: AKRX) today announced the FDA approval of NDA 22-221 for Akten(TM) Ophthalmic Gel 3.5%, a topical, ocular ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE